Treatment Clinical Trials for Multiple Myeloma

Clinical trials are research studies that involve people. The clinical trials on this list are for multiple myeloma treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 237

  • PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse / Refractory Multiple Myeloma

    To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse / refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
    Location: 6 locations

  • Citarinostat and PVX-410 with or without Lenalidomide in Treating Patients with Smoldering Multiple Myeloma

    This phase Ib trial studies the side effects of HDAC inhibitor ACY-241 (citarinostat) and XBP1-US / XBP1-SP / CD138 / CS1 multipeptide vaccine PVX-410 (PVX-410) with or without lenalidomide in treating patients with smoldering multiple myeloma. Citarinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Vaccine therapy, such as PVX-410, may help the body build an effective immune response to kill cancer cells. Biological therapies, such as lenalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Giving citarinostat and PVX-410 with or without lenalidomide may work better in treating patients with smoldering multiple myeloma.
    Location: 6 locations

  • AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia

    At least one dose level of AMG 176 will achieve acceptable safety and tolerability in subjects with relapsed or refractory multiple myeloma and subjects with relapsed or refractory acute myeloid leukemia
    Location: 6 locations

  • Study of AO-176 as Monotherapy and in Combination With Bortezomib / Dexamethasone in Relapsed / Refractory Multiple Myeloma

    Open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) / pharmacodynamics and initial efficacy of AO-176 as monotherapy and in combination with dexamethasone and bortezomib in adults with relapsed / refractory multiple myeloma (MM).
    Location: 6 locations

  • Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

    This study will find the maximum tolerated dose (MTD) of CYNK-001 which contain NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given post Autologous Stem Cell Transplant (ASCT). The safety of this treatment will be evaluated, and researchers will want to learn if NK cells will help in treating Multiple Myeloma.
    Location: 6 locations

  • Ixazomib, Pomalidomide, and Dexamethasone for the Treatment of Recurrent or Refractory Multiple Myeloma

    This phase I / II trial studies the side effects and best dose of the combination of ixazomib, pomalidomide and dexamethasone for treating patients with multiple myeloma that has come back (recurrent) or does not respond to treatment (refractory). Ixazomib may stop the growth of tumor cells by blocking or slowing down a part of cells called proteasomes, therefore preventing proteasomes from doing their job, which is digestion of proteins. The buildup of excess proteins may cause cell death. Dexamethasone may stop white blood cells from traveling to areas myeloma cells are causing damage, and when combined with drugs used to treat myeloma, it sometimes makes those drugs work better. Giving ixazomib, pomalidomide, and dexamethasone may work better in treating patients with multiple myeloma compared to chemotherapy alone.
    Location: 5 locations

  • Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

    This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM). Subjects will receive treatment in 3 phases - induction (6 cycles), consolidation (6 cycles), and maintenance (12 cycles). Each cycle is 28 days.
    Location: 6 locations

  • Study of CLR 131 in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia

    Part A of this study evaluates CLR 131 in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL) / Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL) who have been previously treated with standard therapy for their underlying malignancy. Part B (CLOVER-WaM) is a pivotal efficacy study evaluating IV administration of CLR 131 in patients with WM that failed Bruton's tyrosine kinase inhibitors (BTKi).
    Location: 5 locations

  • A Phase 1 / 2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R / R MM

    An open-label, Phase 1 / 2 study of HPN217 as monotherapy to assess the safety, tolerability and PK in patients with relapsed / refractory multiple myeloma
    Location: 5 locations

  • A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A in Study Participants With Relapsed / Refractory Multiple Myeloma

    This is a Phase 1 / 2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR269A in adults with r / r MM.
    Location: 6 locations

  • A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

    Study CC-99712-MM-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), First-in-Human (FIH) clinical study of CC-99712 in subjects with relapsed and refractory multiple myeloma (MM). The dose escalation part (Part A) of the study will evaluate the safety and tolerability of escalating doses of CC-99712, administered intravenously (IV), to determine the maximum tolerated dose (MTD) and non-tolerated dose (NTD) of CC-99712 using a modified accelerated titration design and Bayesian methodology. The MTD and NTD may be established separately for CC-99712 administered at Q3W and / or Q4W schedules. The expansion part (Part B) will further evaluate the safety and efficacy of CC-99712 administered at or below the MTD in selected expansion cohorts in order to determine the RP2D. One or more dosing regimens may be selected for cohort expansion. All subjects will be treated until confirmed disease progression per IMWG criteria, unacceptable toxicity, or subject / Investigator decision to withdraw.
    Location: 5 locations

  • APG-2575 Study of Safety, Tolerability ,PK / PD in Patients With Hematologic Malignancies

    This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.
    Location: 5 locations

  • A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

    This is a study of venetoclax, daratumumab, and dexamethasone with and without bortezomib combination therapy to evaluate safety, tolerability, and efficacy of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Part 1 includes participants with t(11;14) positive relapsed / refractory (R / R) multiple myeloma who will receive venetoclax in combination with daratumumab and dexamethasone (VenDd); Part 2 includes participants with R / R multiple myeloma who will receive venetoclax in combination with daratumumab, bortezomib, and dexamethasone (VenDVd); Part 3 includes participants with t(11;14) positive R / R multiple myeloma who will receive venetoclax in combination with daratumumab and dexamethasone (VenDd) or daratumumab, bortezomib, and dexamethasone (DVd). Part 1 and Part 2 are non-randomized and will be initiated with a dose-escalation phase in which increasing doses of venetoclax will be given with fixed doses of daratumumab and dexamethasone (Part 1a) or with fixed doses of daratumumab, bortezomib, and dexamethasone (Part 2a). Each dose escalation phase will be followed by a single-arm, open-label expansion phase. Part 3 will include a randomized, open-label expansion phase with participants receiving venetoclax in combination with daratumumab and dexamethasone (VenDd) or daratumumab, bortezomib, and dexamethasone (DVd).
    Location: 8 locations

  • Study of ISB 1342, a CD38 / CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

    The purpose of this study is to determine the safety profile, maximum tolerable dose (MTD) and cohort expansion of single-agent ISB 1342 in subjects with multiple myeloma who have received prior therapies.
    Location: 5 locations

  • Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

    This phase I trial studies the side effects and best dose of MDM2 Inhibitor KRT-232 when given together with carfilzomib, lenalidomide, and dexamethasone in treating patient with multiple myeloma that has come back (relapsed) or has not responded to previous treatment (refractory). KRT-232 (AMG 232) may stop the growth of cancer cells by blocking a protein called MDM2 that is needed for cell growth. Lenalidomide help shrink or slow the growth of multiple myeloma. Drugs used in chemotherapy, such as carfilzomib and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving MDM2 Inhibitor KRT-232, lenalidomide, carfilzomib, and dexamethasone together may work better in treating patients with multiple myeloma.
    Location: 5 locations

  • Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab for the Treatment of Newly Diagnosed, Transplant-Eligible Multiple Myeloma

    This phase II trial investigates how well carfilzomib, lenalidomide, dexamethasone, and isatuximab work in treating patients with newly diagnosed multiple myeloma who are eligible for a transplant. Carfilzomib may work by inhibiting (blocking) multiple myeloma cells from breaking down proteins within the cells, causing a buildup of proteins within multiple myeloma cells, that may lead to cell death. Lenalidomide may work in many ways of attacking tumor cells including activating the immune system against the tumor, and increasing tumor cell death, and decreasing tumor blood vessel growth. Anti-inflammatory drugs, such as dexamethasone lower the body’s immune response and are used with other drugs to treat and kill some types of cancer. Isatuximab is a monoclonal antibody. An antibody is a protein produced in the blood to fight diseases by attacking and killing harmful foreign organisms such as bacteria and viruses. In some diseases, like cancer, the antibody will protect the patient by attaching itself to a target molecule inside the body, which is also a protein. Isatuximab will attach itself to a protein called CD38 located on the surface of immune cells and some cancer cells in the body and can induce the killing of those cells. Giving carfilzomib, lenalidomide, dexamethasone, and isatuximab may help treat patients with multiple myeloma.
    Location: 4 locations

  • Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

    This a Phase I / II randomized trial for patients with relapsed refractory Multiple Myeloma who have relapsed after treatment with prior therapies. The protocol is designed to evaluate two agents, Anti-LAG-3 and Anti-TIGIT, in order to understand their immunologic effects and safety both as single agents and in combination with pomalidomide and dexamethasone. In these arms, patients will be treated with either Anti-LAG-3 or Anti-TIGIT respectively for one cycle as single agent followed by the addition of pomalidomide and dexamethasone in combination for subsequent cycles. A third arm allows patients to be treated with the FDA approved combination of elotuzumab plus pomalidomide and dexamethsone as a control. This arm will thus allow a concurrent standard of care comparator for the experimental arms.
    Location: 4 locations

  • A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

    The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize the safety of each RP2D for selected treatment combinations.
    Location: 5 locations

  • First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

    In the phase 1 portion of the study, the primary objectives are to assess the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine a recommended phase 2 dose regimen (RP2DR) of REGN5459 as monotherapy in patients with relapsed or refractory multiple myeloma (MM) who have exhausted all therapeutic options that are expected to provide meaningful clinical benefit. In the phase 2 portion of the study, the primary objective is to assess the preliminary anti-tumor activity of REGN5459 as measured by objective response rate (ORR). In the phase 1 and phase 2 portion, the secondary objectives of the study are: - To assess the preliminary anti-tumor activity of REGN5459 as measured by duration of response (DOR), progression-free survival (PFS), rate of minimal residual disease (MRD) negative status, and overall survival (OS) - To evaluate the pharmacokinetic (PK) properties of REGN5459 - To characterize the immunogenicity of REGN5459 - To evaluate the effects of REGN5459 on patient-reported quality of life (QoL), symptoms, functioning and general health status In the phase 1 portion of the study only, the secondary objective of the study is to assess the preliminary anti-tumor activity of REGN5459 as measured by ORR. In the phase 2 portion of the study only, the secondary objective of the study is to evaluate the safety and tolerability of REGN5459.
    Location: 5 locations

  • Study of Lenalidomide / Ixazomib / Dexamethasone / Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

    A randomized Phase II clinical trial will be conducted to assess the impact on progression free survival (PFS) with the addition of ixazomib and daratumumab to lenalidomide as a maintenance treatment following induction with lenalidomide, ixazomib, dexamethasone, and daratumumab. Patients will be randomized to either: Arm A: 12 cycles of lenalidomide, ixazomib, daratumumab, and dexamethasone followed by lenalidomide until disease progression or unacceptable toxicity or a maximum of 2 years of maintenance therapy. Arm B: 12 cycles of lenalidomide, ixazomib, daratumumab and dexamethasone, followed by lenalidomide, ixazomib, and daratumumab until disease progression or unacceptable toxicity or a maximum of 2 years maintenance therapy.
    Location: 5 locations

  • Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma

    This phase II trial studies how well daratumumab, pomalidomide, and dexamethasone work in treating patients with multiple myeloma that has come back (relapsed). Immunotherapy with daratumumab may induce changes in body’s immune system and may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as pomalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving daratumumab with dexamethasone and pomalidomide may work bettering in treating patient compared to dexamethasone and pomalidomide alone.
    Location: 7 locations

  • CB-839 HCl in Combination with Carfilzomib and Dexamethasone in Treating Patients with Recurrent or Refractory Multiple Myeloma

    This phase I trial studies the best dose of CB-839 HCl when given together with carfilzomib and dexamethasone in treating patients with multiple myeloma that has come back or does not respond to previous treatment. CB-839 HCl and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving CB-839 HCl, carfilzomib, and dexamethasone may work better in treating patients with multiple myeloma.
    Location: 4 locations

  • Study of Ibrutinib in Combination With Revlimid / Dexamethasone in Relapsed / Refractory Multiple Myeloma

    This is a registration, open-label phase 1 study of the combination of ibrutinib / lenalidomide: / dexamethasone in women and men with relapsed / refractory multiple myeloma.
    Location: 4 locations

  • Isatuximab and Carfilzomib with or without Dexamethasone and Lenalidomide in Treating Patients with Relapsed or Refractory Multiple Myeloma

    This phase Ib trial studies the side effects and best dose of isatuximab when given together with carfilzomib with or without dexamethasone and lenalidomide in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) or has not respond to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as isatuximab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving isatuximab and carfilzomib with or without dexamethasone and lenalidomide may be a better treatment for patients with multiple myeloma.
    Location: 4 locations

  • Laboratory-Treated T Cells in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Recurrent or Refractory B-Cell Lymphoma or Multiple Myeloma

    This phase I trial studies the side effects of laboratory-treated T cells in treating patients with B-cell chronic lymphocytic leukemia, B-cell lymphoma, or multiple myeloma that has come back or has not gone away after treatment. This study combines two different ways of fighting disease, antibodies (proteins that protect the body from bacterial and other diseases) and T cells (special infection-fighting blood cells that can kill other cells, including cancer cells). Treating the T cells in the laboratory by adding an antibody may help the T cells last longer in the body and kill more cancer cells.
    Location: 4 locations